Trial · NCT06474078
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
NCT06474078, Not applicable, Completed, Chang Gung Memorial Hospital; results first posted 2025-09-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN. Trials, record NCT06474078. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06474078
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
- NCT number
- NCT06474078
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Chang Gung Memorial Hospital
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
- Interventions
- Tofacitinib
- First posted
- 2024-06-25
- Last updated
- 2025-09-16
- Results first posted
- 2025-09-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Skin Healing Time, Day, Medium [Full Range] | days | Healing was defined as complete re-epithelialization (i.e., the complete absence of erosions). We recorded the time taken by the skin to heal. |
| Primary | Complete Skin Healing Time, Day, Mean [Full Range] | days | Healing was defined as complete re-epithelialization (i.e., the complete absence of erosions). We recorded the time taken by the skin to heal. |
| Secondary | Length of Hospitalization | Duration of hospital stay up to 3 months | Length of hospitalization and Duration of hospitalization days |
| Secondary | Mortality | up to 1 year | Number of participants with mortality at 30 days, 3 months and 1 year. Mortality monitoring is considered for the underlying SJS/TEN disease. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete Skin Healing Time, Day, Medium [Full Range] | days | We determined if the enrolled participants had SJS/TEN using the criteria and histopathological examinations. | days | MEDIAN |
| PRIMARY | Complete Skin Healing Time, Day, Mean [Full Range] | days | We determined if the enrolled participants had SJS/TEN using the criteria and histopathological examinations. | days | MEAN |
| SECONDARY | Length of Hospitalization | Duration of hospital stay up to 3 months | days | MEAN | |
| SECONDARY | Mortality | up to 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Skin Healing Time, Day, Medium [Full Range] | Tofacitinib Treatment | 10.0 | Full Range 6 to 15 | days | |
| Complete Skin Healing Time, Day, Mean [Full Range] | Tofacitinib Treatment | 10.1 | Full Range 6 to 15 | days | |
| Length of Hospitalization | Tofacitinib Treatment | 22.4 | Standard Deviation 15.6 | days | |
| Mortality | Tofacitinib Treatment | 0 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tofacitinib Treatment | 20 | |
| Overall Study | COMPLETED | Tofacitinib Treatment | 20 | |
| Overall Study | NOT COMPLETED | Tofacitinib Treatment | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abnormal liver function | Hepatobiliary disorders | Tofacitinib Treatment | 3 | 20 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tofacitinib Treatment | 0 | 20 |
| Total, other adverse events | Tofacitinib Treatment | 3 | 20 |
| Total, serious adverse events | Tofacitinib Treatment | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06474078
GET https://conductscience.org/api/trials/v1/NCT06474078/registered